

# Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

## B6CBA-Tg(HDexon1)62Gpb/1J

RRID:IMSR\_JAX:002810

Type: Organism

---

### Proper Citation

RRID:IMSR\_JAX:002810

---

### Organism Information

**URL:** <https://www.jax.org/strain/002810>

**Proper Citation:** RRID:IMSR\_JAX:002810

**Description:** Mus musculus with name B6CBA-Tg(HDexon1)62Gpb/1J from IMSR.

**Species:** Mus musculus

**Synonyms:** B6CBA-TgN(HDexon1)62Gpb. B6CBA-Tg(HDexon1)62oGpb/J

**Notes:** gene symbol note: huntingtin|transgene insertion 62; Gillian Bates; mutant strain: HTT|Tg(HDexon1)62Gpb

**Affected Gene:** huntingtin|transgene insertion 62; Gillian Bates

**Genomic Alteration:** transgene insertion 62; Gillian Bates

**Catalog Number:** JAX:002810

**Database:** JAX Mice and Services

**Database Abbreviation:** JAX

**Availability:** live

**Organism Name:** B6CBA-Tg(HDexon1)62Gpb/1J

**Record Creation Time:** 20250513T053635+0000

**Record Last Update:** 20260725T044344+0000

---

### Ratings and Alerts

No rating or validation information has been found for B6CBA-Tg(HDexon1)62Gpb/1J.

No alerts have been found for B6CBA-Tg(HDexon1)62Gpb/1J.

---

## Data and Source Information

**Source:** [Integrated Animals](#)

**Source Database:** JAX Mice and Services

---

## Usage and Citation Metrics

We found 317 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Oberländer K, et al. (2025) Inhba, Homer1 and Bdnf are major targets of transcriptomic dysregulation by neurodegenerative disease-associated excitotoxic NMDA receptor signaling. *Communications biology*, 8(1), 1743.

Frosch M, et al. (2025) Microglia-neuron crosstalk through Hex-GM2-MGL2 maintains brain homeostasis. *Nature*, 646(8086), 913.

Pradhan S, et al. (2025) Huntingtin preserves mitochondrial genome integrity in neurons, which is impaired in Huntington's disease. *bioRxiv : the preprint server for biology*.

Tung YS, et al. (2025) Insulin-like growth factor 2 reduces Huntington's disease aggregates via AKT and NF- $\kappa$ B signaling in huntington's disease. *Cell & bioscience*, 15(1), 109.

Bosica M, et al. (2025) Coiled-Coil Structures Mediate the Intercellular Propagation of Huntingtin. *International journal of molecular sciences*, 26(17).

Cheng CY, et al. (2025) The therapeutic potential of (R)-carvedilol in Huntington's disease through enhancement of autophagy-lysosomal pathway via GSK-3 $\beta$  inhibition. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 22(3), e00557.

Rusmini P, et al. (2025) Impairment of lysosomal quality control in Huntington disease. *Cell death & disease*, 16(1), 762.

Ikefuama EC, et al. (2025) Presymptomatic targeted circuit manipulation for ameliorating Huntington's disease pathogenesis. *iScience*, 28(3), 112022.

Kang YK, et al. (2025) Emergence of CpG-cluster blanket methylation in aged tissues: a novel signature of epigenomic aging. *Nucleic acids research*, 53(9).

Rubio C, et al. (2025) Animal Models for the Study of Neurological Diseases and Their Link to Sleep. *Biomedicines*, 13(8).

Sapp E, et al. (2025) Mutant huntingtin exon 1 protein detected in mouse brain with neoepitope antibody: effects of CAG repeat expansion, MutS Homolog 3 silencing and aggregation. *Brain communications*, 7(5), fcaf314.

Jiménez-Jiménez FJ, et al. (2025) Oxidative Stress in Huntington's Disease. *Biomolecules*, 15(4).

Kachemov M, et al. (2025) Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum. *Brain : a journal of neurology*, 148(4), 1212.

Simmons DA, et al. (2025) Human striatal progenitor cells that contain inducible safeguards and overexpress BDNF rescue Huntington's disease phenotypes. *Molecular therapy. Methods & clinical development*, 33(1), 101415.

Gao R, et al. (2025) Decoding Microglial Polarization and Metabolic Reprogramming in Neurodegenerative Diseases: Implications for Disease Progression and Therapy. *Aging and disease*, 17(1), 91.

Simmons DA, et al. (2025) Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 22(2), e00495.

Tung CW, et al. (2025) Exploring Cordycepin as a Neuroprotective Agent in Huntington's Disease: In Vitro and In Vivo Insights. *Pharmacology research & perspectives*, 13(2), e70091.

Fernández G, et al. (2025) Restoring endogenous Dlg4/PSD95 expression by an artificial transcription factor ameliorates cognitive and motor learning deficits in the R6/2 mouse model of Huntington's disease. *Clinical epigenetics*, 17(1), 100.

Everix L, et al. (2025) Assessment of changes in synaptic density in the zQ175DN mouse model of Huntington's disease: a [18F]SynVesT-1 study. *NeuroImage. Clinical*, 46, 103800.

König J, et al. (2025) Examination of Anti-Inflammatory Effects After Propionate Supplementation in the R6/2 Mouse Model of Huntington's Disease. *International journal of molecular sciences*, 26(7).